INOVIO Announces Publication of Phase 1 Data from its COVID-19 DNA Vaccine Candidate, INO-4800 in The Lancet’s EClinicalMedicine
The Pharma Data
DECEMBER 23, 2020
All 38 subjects who were evaluable for immunogenicity had balanced cellular and humoral immune responses following the second dose of INO-4800. Only 6 related Grade 1 adverse events in 5 subjects were observed, primarily mild injection site reactions (e.g., ClinicalTrials.gov identifier: NCT04336410.
40 
Let's personalize your content